“Cannabidiol may not only be a faster-acting antidepressant than conventional drugs but also improve the response to such drugs when taken in combination with them.”
CBD has previously demonstrated immunosuppressant properties which encouraged a new study examining the effectiveness of CBD as a treatment therapy option for MS patients.
Since the discovery that the endocannabinoid system is involved in emotional memory processing, researchers have begun to examine whether cannabidiol, or CBD, could be an effective therapeutic treatment option for those suffering from PTSD.
The study confirmed that CBD does in fact seem to possess anti-anxiety properties, which are triggered by CBD’s effect on the limbic and paralimbic brain areas.
In April 2017, European researchers published a study in the Journal of Neuropharmacology that demonstrated the neuroprotective effect of CBD in a rat model of AIS.
Cannabidiol has demonstrated, in studies, to have antiepileptic properties and has had widespread success as a treatment therapy for various types of seizure disorders.
The study confirmed that CBD was successfully able to control RBD symptoms in Parkinson’s patients and was published in the Journal of Clinical Pharmacy and Therapeutics.